Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company’s ABS-201 (anti-PRLR) program for and ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, falls squarely in the high-risk, high-reward category. The firm has also seen success providing AI tools and partnership to other players in the biotech and pharma space, including major pl ...

Absci TodayABSIAbsci$3.62 -0.07 (-1.77%) 52-Week Range$2.01▼$6.33Price Target$7.98Add to WatchlistThe biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, Absci Corp. NASDAQ: ABSI falls squarely in the high-risk, high-reward category. The compan ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying SNPS stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Company Overview - Absci Corporation (NASDAQ:ABSI) was founded in 2018 and is headquartered in Seattle, focusing on integrating deep learning with high-throughput lab automation for biologics design and optimization at scale [2] - The company utilizes its Integrated Drug Creation (IDC) platform, which combines proprietary algorithms with protein engineering to rapidly develop antibody and enzyme candidates for pharmaceutical partners and its own pipeline [2] Recent Developments - Absci recently expanded its partnership with Almirall, launching a second program targeting chronic skin diseases, which builds on the successful delivery of an AI-designed antibody [3] - The company appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders, expected to enter clinical evaluation in early 2026 [3] Technological Advancements - Absci announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities [4] - The partnership with AMD includes a strategic investment, providing access to advanced chip technology and cloud resources for scaling model training and data processing [4] Financial Position - Absci secured $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028 [5] - The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation's AI infrastructure for next-generation drug discovery [5]

Group 1 - Advanced Micro Devices Inc. (AMD) is recognized as a top tech stock to buy, particularly highlighted by Cathie Wood [1] - Absci Corporation has formed a strategic partnership with Oracle Cloud Infrastructure and AMD to enhance its AI-powered drug discovery platform [1][2] - The partnership will utilize AMD's 5th Generation EPYC processor and RDMA cluster network, improving low-latency networking and high-throughput capabilities for Absci's platform [2] Group 2 - Sean McClain, Founder and CEO of Absci, emphasized the collaboration aims to combine advanced AI models with superior infrastructure [3] - AMD specializes in high-performance computing technologies, including CPUs, GPUs, and FPGAs, serving various sectors such as PCs, data centers, and gaming [3]

Core Insights - Absci (ABSI.US) announced a collaboration with Oracle (ORCL.US) and AMD (AMD.US) to accelerate AI-driven drug development [1] - The partnership will utilize Oracle's AI infrastructure and AMD's hardware in Absci's generative AI Drug Creation Platform [1] - The CEO of Absci emphasized that this collaboration will enhance the efficiency of delivering new therapies to patients and establish a technological foundation for next-generation AI-driven drug development processes [1] Company Developments - Absci is based in Vancouver, Washington, and focuses on biotechnology [1] - The announcement coincided with the Oracle Health and Life Sciences Summit held from September 9 to 11 in Orlando, Florida [1] - At the summit, Oracle showcased advancements in healthcare technology, including AI capabilities in its Oracle Fusion Cloud Application, aimed at streamlining supply chain operations in the healthcare industry [1]

Core Insights - Absci Inc. has partnered with Oracle Corporation and AMD to enhance its generative AI-driven drug discovery capabilities [1][2] - The collaboration aims to streamline infrastructure and accelerate biologics design cycles through advanced AI technologies [1][2] Group 1: Collaboration and Technology - Absci's generative AI Drug Creation Platform utilizes Oracle Cloud Infrastructure (OCI) and AMD's hardware to improve drug discovery processes [1] - The partnership allows for large-scale molecular-dynamics simulations and comprehensive antibody design, significantly speeding up development and operations [2] Group 2: Infrastructure and Performance - The integration of fifth-generation AMD EPYC processors and RDMA cluster networking in OCI's bare metal instances provides the necessary low-latency networking and throughput for extensive model training [3] - Direct access to AMD GPUs in a flat-network supercluster has minimized hypervisor overhead and reduced inter-GPU latency to as low as 2.5 microseconds, enhancing data streaming capabilities [4] Group 3: Market Reaction - Following the announcement, Absci's stock price increased by 10.50%, reaching $2.63 [5]

Core Viewpoint - Absci, an artificial intelligence drug developer, experienced a significant stock increase of over 21%, reaching a peak of $2.89, following the announcement of a collaboration with Oracle and AMD to enhance AI-driven drug discovery processes [1] Company Summary - Absci announced a partnership with Oracle and AMD to accelerate its generative AI-driven drug discovery platform [1] - The collaboration will leverage Oracle's AI infrastructure and AMD's latest hardware to improve the drug discovery process [1]

Core Insights - Absci announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery initiatives [2] Group 1: Collaboration Details - The partnership will leverage Oracle's AI infrastructure and AMD's technology to accelerate drug discovery processes [2]